News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Oral Presentation at American Society of Clinical Oncology from Intergroup Phase III Study (CALGB 100104) Evaluates Continuous REVLIMID® in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant


6/28/2010 3:12:19 PM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced that data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the annual meeting of the American Society of Clinical Oncology.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES